Infection Prophylaxis in Patients with Multiple Myeloma Receiving Bispecific Antibody Therapy

Project Summary:

T-cell redirecting immunotherapies, notably bispecific antibody therapy, have ushered in a revolutionary era in treating relapsed and refractory multiple myeloma (MM). These therapies primarily target B-cell maturation antigen (BMCA), G protein–coupled receptor, family C, group 5, member D (GPRC5D), and Fc receptor-homolog 5 (FcRH5) antigen on MM cells. Despite their transformative potential, these innovative treatments are associated with a substantial risk of infectious complications.

The overarching goal of this project is to assess the utilization patterns of infection prophylaxis, identify key factors that impact its adoption, and analyze infection trends following the implementation of infection prevention strategies in MM patients receiving bispecific antibody therapy. By offering comprehensive infection monitoring and prevention measures, the researchers aim to contribute to the evolution of immunotherapy strategies for MM, ultimately elevating the standard of patient care within the realm of these transformative therapies.